{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:36:46Z","timestamp":1787841406527,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:p>This study assessed the efficacy and safety of ombitasvir\/paritaprevir\/ritonavir (OBV\/PTV\/r) combined with dasabuvir (DSV) for treating hepatitis C genotype 4 (GT4) and genotype 1 (GT1) in patients with stage 4 or 5 chronic kidney disease (CKD). Among 88 patients, including treatment-na\u00efve and Peginterferon\/Ribavirin (RBV)-experienced, treated with OBV\/PTV\/r\u00b1RBV (dosed between 200 mg per week to daily) and additional DSV for GT1, 94.3% achieved sustained virologic response at 12 weeks (SVR12), demonstrating high efficacy. RBV was used at the discretion of the treating physician. The treatment was well-tolerated, with two non-treatment-related deaths reported. The findings suggest that a 12-week regimen of OBV\/PTV\/r\u00b1DSV is highly effective and safe for GT1 and GT4 patients with advanced CKD, regardless of baseline characteristics.<\/jats:p>","DOI":"10.4103\/jpbs.jpbs_143_24","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T04:00:08Z","timestamp":1720238408000},"page":"S2224-S2227","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Ombitasvir\/Paritaprevir\/Ritonavir Plus Dasabuvir in Treating HCV Genotypes 1 and 4 in Patients with Advanced Chronic Kidney Disease"],"prefix":"10.4103","volume":"16","author":[{"given":"Badr M.","family":"Aljarallah","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hepatology, College of Medicine, Qassim University, Buraydah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection:New estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"R2-20240829","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015:A modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"(Suppl 2)","key":"R3-20240829","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.4103\/1319-3767.188067","article-title":"SASLT guidelines:Update in treatment of Hepatitis C virus infection","volume":"22","author":"Alghamdi","year":"2016","journal-title":"Saudi J Gastroenterol"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0272-6386(12)80930-9","article-title":"Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members","volume":"22","author":"Niu","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"R5-20240829","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2010.29.1500","article-title":"Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma:Long-term predictors from a community-based cohort study","volume":"28","author":"Lee","year":"2010","journal-title":"J Clin Oncol"},{"key":"R6-20240829","doi-asserted-by":"crossref","first-page":"e100790","DOI":"10.1371\/journal.pone.0100790","article-title":"Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"R7-20240829","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.transproceed.2019.01.011","article-title":"Health indicators for renal replacement therapy in Saudi Arabia","volume":"51","author":"Shaheen","year":"2019","journal-title":"Transplant Proc"},{"key":"R8-20240829","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/jvh.12422","article-title":"Interferon-free, direct-acting antiviral therapy for chronic hepatitis C","volume":"22","author":"Gutierrez","year":"2015","journal-title":"J Viral Hepat"},{"key":"R9-20240829","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"key":"R10-20240829","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ekir.2018.10.003","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir in patients with hepatitis C virus genotype 1 or 4 infection and advanced kidney disease","volume":"4","author":"Lawitz","year":"2019","journal-title":"Kidney Int Rep"},{"key":"R11-20240829","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jvh.12664","article-title":"Therapy with ombitasvir\/paritaprevir\/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment:A multicentre experience","volume":"24","author":"Mu\u00f1oz-G\u00f3mez","year":"2017","journal-title":"J Viral Hepat"},{"key":"R12-20240829","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","article-title":"Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I):A randomised, open-label trial","volume":"385","author":"H\u00e9zode","year":"2015","journal-title":"Lancet"},{"key":"R13-20240829","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N Engl J Med"},{"key":"R14-20240829","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/apt.13790","article-title":"Real-world effectiveness and safety of ombitasvir\/paritaprevir\/ritonavir\u00b1dasabuvir\u00b1ribavirin in hepatitis C:AMBER study","volume":"44","author":"Flisiak","year":"2016","journal-title":"Aliment Pharmacology Ther"},{"key":"R15-20240829","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study):A combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"R16-20240829","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.kint.2018.02.019","article-title":"Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4\/5 severe chronic kidney disease is safe and effective","volume":"94","author":"Alric","year":"2018","journal-title":"Kidney Int"},{"key":"R17-20240829","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Journal of Pharmacy and Bioallied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_143_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:53:35Z","timestamp":1787838815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_143_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":17,"journal-issue":{"issue":"Suppl 3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jpbs.jpbs_143_24","relation":{},"ISSN":["0976-4879","0975-7406"],"issn-type":[{"value":"0976-4879","type":"print"},{"value":"0975-7406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-02-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}